---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-030014"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:47:45.147937+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology Q3 2023 net income $5.8M, reverses prior-year loss; revenue $56.1M

## Summary
- Product revenue net $51.6M (down 5% YoY from $54.3M); total revenue $56.1M.
- GAAP net income $5.8M ($0.12/diluted) vs net loss $0.4M in Q3 2022.
- Non-GAAP adjusted net income $8.3M ($0.17/diluted) vs $2.5M prior year.
- Cash and securities $85.0M; net cash from operations $10.7M in Q3.
- Q4 product revenue guidance $56-59M; FDA accepted IND for alisertib, granted orphan drug designation for SCLC.

## SEC filing metadata
- accession: 0001437749-23-030014
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774923030014/0001437749-23-030014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774923030014/pbyi20231030_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-030014
- JSON: https://secwatch.observer/filing/0001437749-23-030014.json
- Plain text: https://secwatch.observer/filing/0001437749-23-030014.txt

## Key facts
- Earnings Releases
  PUMA BIOTECHNOLOGY, INC. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 2, 2023, Puma Biotechnology, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401667/000143774923030014/0001437749-23-030014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.